If trade optimism is truly feeding these stock records, then get the confetti ready.
Reports that the U.S. may drop some China tariffs to seal a “phase one” deal are boosting stock futures on Tuesday. That’s a day after all three major U.S. indexes nailed record closes.
But Lori Calvasina, RBC Capital Markets’ head of U.S. equity strategy, is wary of those highs and offers five reasons why investors should be too, in our call of the day.
In a note to clients, she says she’s sticking to RBC’s year-end S&P 500
target of 2,950, even as the index pushes above 3,000. Here’s why:
1) “Euphoric” U.S. equity futures positioning among asset managers is nearing July 2019, September 2018 and January 2019 peaks that are in line with highs seen just before the global financial crisis. That means stocks could be vulnerable to bad news.
2) Valuations in the U.S. equity market are back to late-2017 highs, and Calvasina says improvement from here may be tough given the Federal Reserve is expected to pause on further interest rate cuts.
3) Earnings forecasts for 2020 are too high.
4) Stocks are already accounting for the benefits of a phase one trade deal, which Calvasina doubts would undo damage that’s been done to business confidence.
5) As of Nov. 4, the S&P 500 has rallied more than 30% from the December 2018 low. That’s similar to rallies seen off index lows in 2010, 2011 and 2016, and as her chart shows, each of those years had market pauses along the way:
“The new thought we offer this week is that we haven’t learned anything in the current reporting season that justifies euphoric positioning and peak valuations. Reporting season has been better than feared, but the overall tone around demand/macro, tariffs and cost savings all sounds very familiar – it’s what companies have been saying all year,” says Calvasina.
futures are higher. European stocks
are near four-year highs, and Asian markets also finished up.
Our chart comes from the World Gold Council. On Tuesday, the industry body reported the biggest exchange-traded fund inflows for gold in three years, due to accommodative monetary policies, safe-haven demand and investors chasing some big gains.
It’s been a strong year for gold
which is up 17% so far this year, putting it on a par with the Dow industrials.
Tuesday’s earnings list includes pharmaceutical groups Mylan
plus the first set of results from exercise equipment maker Peloton
shares are stumbling after the ride-hailing service reported another mega loss. Shares of fast-food restaurant Shake Shack
are also sliding as same-store sales and its outlook missed forecasts.
Trade balance data will hit early, followed by the Markit services purchasing managers’ index, the ISM non-manufacturing index and job openings. There are also a lot of Fed speakers this week.
$1.8 million — That’s the cost of a single-dose drug developed by Bluebird Bio
for a rare blood disorder that has plagued Sicilians for centuries.
Financial troubles can cause post-traumatic stress disorder
Eight U.S. citizens, including children, gunned down in Mexican cartel crossfire
Deadly scuffle over a wildly popular chicken sandwich
There’s a new word for being single: self-partnered
Need to Know starts early and is updated until the opening bell, but sign up here to get it delivered once to your email box. Be sure to check the Need to Know item. The emailed version will be sent out at about 7:30 a.m. Eastern.